Solved Case Analysis: Pricing the EpiPen: This is Going to Sting by Thomas J. Steenburgh


Get the Best Analysis to this Case Study written by MBA/CFA writers.

**Solution would be delivered to your registered email address within next 4 days. If you want the solution any earlier drop an email at  Click Here to see how it works



This case examines the public controversy that erupted over the increasingly high price of EpiPens. Mylan Inc. (Mylan), a generic drug maker, bought the EpiPen product line from Merck in 2007. Since that time, the company both invested in marketing to raise awareness for the drug and dramatically increased the price, lifting it from $100 to $600 per two pack in the U.S. In 2016, simmering consumer anger about the high prices of pharmaceutical drugs finally reached a boiling point and a media firestorm ensued. The case challenges students to think about the role of fairness in pricing. How can Mylan justify the dramatic price increases? How can it justify the variation in prices across countries, as an EpiPen is priced at an equivalent of $85 in France? The case challenges students to think about how they would handle a public controversy. The EpiPen case is well suited for students in MBA, MBA for Executives, and executive education programs. For MBA students, it can be placed in first-year marketing, pricing, or marketing communications courses. For executives, it can serve as a vehicle to discuss both ethical issues of pricing and how to handle a public controversy.

Publishing Authority:

Darden Business Publishing – University of Virginia


There are no reviews yet.

Be the first to review “Solved Case Analysis: Pricing the EpiPen: This is Going to Sting by Thomas J. Steenburgh”

Your email address will not be published. Required fields are marked *